



PATENT
Customer No. 22,852
Attorney Docket No. 08702.0083-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
Man Sung Co et al.)
Application No.: 09/501,102) Group Art Unit: 1644
Filed: February 9, 2000) Examiner: Not Yet Assigned
For: HUMANIZED)
IMMUNOGLOBULIN REACTIVE)
WITH B7 MOLECULES AND)
METHODS OF TREATMENT)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CORRECTED FILING RECEIPT

We are forwarding herewith a copy of a Filing Receipt containing errors for the above-identified patent application. The errors are the omissions of inventors Garvin Warner and Stuart Friedrich, and the state of residence of Bonita Rup which should be MA, not MS. Corrections are shown in ink on the attached copy.


It is respectfully requested that a corrected Filing Receipt be issued as soon as possible.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: *March 8, 2004*

By: *E Stewart Mittler*
E. Stewart Mittler
Reg. No. 50,316



UNITED STATES PATENT AND TRADEMARK OFFICE

RDB/RMM/ESM

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/501,102	02/09/2000	1644	1408	08702.0083-00000	33	18	5

Finnegan Henderson Farabow Garrett & Dunn, LLP
1300 I Street N W
Washington, DC 20005-3315

RECEIVED

SEP - 8 2003

CONFIRMATION NO. 3404

UPDATED FILING RECEIPT



OC000000010811116

Date Mailed: 09/04/2003

FINNEGAN, HENDERSON, FARABOW,
GARRETT AND DUNN, LLP

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Man Sung Co, Cupertino, CA;
Maximiliano Vasquez, Palo Alto, CA;
Beatriz Carreno, Acton, MA;
Abbie Cheryl Celniker, Newton, MA;
Mary Collins, Natick, MA;
Samuel Goldman, Acton, MA;
Gary S. Gray, Brookline, MA;
Andrea Knight, Hampton Falls, NH;
Denise O'Hara, Reading, MA;
Bonita Rup, Reading, MA;
Geertruida M. Veldman, Sudbury, MA;

Garvin Warner, Windham, NH
Stuart Friedrich, Melrose, MA.

Domestic Priority data as claimed by applicant

This application is a CIP of 09/339,596 06/24/1999
which is a CIP of 09/249,011 02/12/1999

Foreign Applications

If Required, Foreign Filing License Granted: 04/24/2000

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

✓ 9-8-03
L

DATA 9/8/03

Early Publication Request: No

Title

Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith

Preliminary Class

424

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).